Drug Approval | June 23, 2026
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Pharma powerhouse names Cecile Guegan interim finance chief
Bolstering neuroscience push with late-stage Tourette therapy
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Subscribe To Our Newsletter & Stay Updated
